Company Encyclopedia
View More
name
Picard Medical
PMI.US
Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the USA, Europe, and internationally. The company was incorporated in 2021 and is based in Tucson, Arizona.
1.407 T
PMI.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking81/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE234.93%A
    • Profit Margin-661.82%E
    • Gross Margin-10.95%E
  • Growth ScoreC
    • Revenue YoY8.81%B
    • Net Profit YoY-54.39%D
    • Total Assets YoY11.27%B
    • Net Assets YoY152.65%A
  • Cash ScoreC
    • Cash Flow Margin-14.80%D
    • OCF YoY8.81%B
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreC
    • Gearing Ratio41.07%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Picard Medical Unveils Promising Artificial Heart Data

    Picard Medical, Inc. presented promising in vitro data on their Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support. The data showed comparable autoregulation and afterload independence to the SynCardia Total Artificial Heart, indicating potential for stable hemodynamic performance and surgical feasibility, paving the way for future clinical applications.

    Tip Ranks·
    US
    PMI
    +82.67%
    Tip Ranks·
    US
    PMI
    +82.67%

    Picard Medical, Inc. Presents Emperor Total Artificial Heart Data

    Picard Medical, Inc. presented in vitro data on the Emperor Total Artificial Heart at an international conference on December 4, 2025. The Emperor TAH eliminates the need for external pneumatic drivers, demonstrates autoregulation and afterload independence, and has confirmed surgical feasibility and performance through its first in vivo implantation. The results support future chronic animal studies and clinical translation.

    TradingView·
    US
    PMI
    +82.67%
    TradingView·
    US
    PMI
    +82.67%

    Picard Medical CEO to Present Emperor Total Artificial Heart at CSI Focus D-HF in Frankfurt

    Picard Medical Inc.'s CEO, Patrick NJ Schnegelsberg, will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt on December 6, 2025. The presentation will take place from 13:00 to 13:45 CET during the “Durable Mechanical Circulatory Support” session.

    Reuters·
    US
    PMI
    +82.67%
    Reuters·
    US
    PMI
    +82.67%

    Picard Medical Unveils Fully Implantable Emperor Total Artificial Heart at ISMCS 2025

    Picard Medical Inc. will present its next-generation, fully implantable Emperor Total Artificial Heart at the ISMCS 2025 in Vienna. The presentation, led by Engineering Project Manager Duffy Elmer, will cover benchtop performance data and improvements in patient mobility and quality of life. The event is scheduled for December 4, 2025, during the Mini Oral Session 3. This information was originally published by Picard Medical via the U.S. SEC's EDGAR system.

    Reuters·
    US
    PMI
    +82.67%
    Reuters·
    US
    PMI
    +82.67%

    Picard Medical, Inc. Reports Increased Revenue Amidst Financial Challenges

    Picard Medical, Inc. reported a significant increase in Q3 revenues to $1.187 million, up from $881,000 last year, driven by product sales and rental income. Despite this, the company faced a net loss of $10.426 million, up from $6.206 million previously. The company is investing in R&D and has restructured financially, including an IPO and debt-to-equity conversion. Operating expenses remain high, and liquidity challenges persist. Picard Medical is exploring financing options to support its strategic plan and aims for profitability through innovation and market expansion.

    Tip Ranks·
    US
    PMI
    +82.67%
    Tip Ranks·
    US
    PMI
    +82.67%
    © 2025 Longbridge｜Disclaimer